Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | CDK4 | P11802 | 3/20 | 0.35 |
| ▸ | CCND1 | P24385 | 3/20 | 0.35 |
| ▸ | CCND2 | P30279 | 3/20 | 0.35 |
| ▸ | CCND3 | P30281 | 3/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.32 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | LTA4H | P09960 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | DRD4 | P21917 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2427828 | 0.90 | GPR119 (0.37) | GPR119CYP11B2CDK4CCND1CCND2 | |
| SCHEMBL2386613 | 0.81 | GPR119 (0.39) | GPR119CYP11B2CDK4CCND1CCND2 | |
| SCHEMBL1103887 | 0.80 | GPR119 (0.64) | GPR119CYP11B2LMNACHRM4 | |
| SCHEMBL470594 | 0.79 | GPR119 (0.48) | GPR119OPRK1ALOX5APLMNA | |
| SCHEMBL19450682 | 0.78 | LMNA (0.41) | GPR119OPRK1LMNAPIK3CAMTOR | |
| SCHEMBL148262 | 0.77 | GPR119 (0.44) | GPR119OPRK1ALOX5APLMNA | |
| SCHEMBL14730194 | 0.74 | OPRK1 (0.40) | GPR119OPRK1LMNA | |
| Hydrochloric Acid SCHEMBL14723194 | 0.74 | SMN1; SMN2 (0.44) | GPR119MEN1KMT2ALMNA | |
| SCHEMBL2372332 | 0.74 | GPR119 (0.59) | GPR119 | |
| Hydrochloric Acid SCHEMBL14723195 | 0.73 | OPRK1 (0.39) | GPR119OPRK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2377864-A1 | Piperidine GPCR agonists | Prosidion Limited (GB) | 2011-10-19 | — | — | EP | disclosed |
| EP-2114935-B1 | PIPERIDINE GPCR AGONISTS | PROSIDION LTD (GB) | 2011-07-20 | — | — | EP | disclosed |
| US-20100286112-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2010-11-11 | — | — | US | disclosed |
| US-20100105732-A1 | PIPERIDINE GPCR AGONISTS | PROSIDION LIMITED (GB) | 2010-04-29 | — | — | US | disclosed |
| US-20100105732-A1 | PIPERIDINE GPCR AGONISTS | PROSIDION LIMITED (GB) | 2010-04-29 | — | — | US | disclosed |
| US-20100105732-A1 | PIPERIDINE GPCR AGONISTS | PROSIDION LIMITED (GB) | 2010-04-29 | — | — | US | disclosed |
| EP-2114935-A1 | PIPERIDINE GPCR AGONISTS | Prosidion Limited (GB) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008081207-A1 | PIPERIDINE GPCR AGONISTS | PROSIDION LIMITED (GB) | 2008-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286112-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | GPR119, DPP4, DPP9 | GPR119 1/4885CYP11B2 617/4885CDK4 1966/4885 |
| US-20100105732-A1 | PIPERIDINE GPCR AGONISTS | GPR119, GPR27, GLP1R | GPR119 1/4885CYP11B2 1395/4885CDK4 3216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.